Cortendo AB Upgraded to the NOTC A-List

 Partille,  Sweden  –  Cortendo  AB  (publ)  (CORT)  today  announced  that  the   company  has  successfully  upgraded  its  listing  status  to  the  NOTC  A-­‐List.     Previously,  Cortendo  had  been  registered  on  the  B-­‐List.    Registration  on  the   NOTC  A-­‐List  will  facilitate  dissemination  of  timely  and  relevant  information   on  the  company  and  its  shares  based  on  the  listing  requirements  of  the  NOTC   A-­‐list.      

“This  advancement  to  the  NOTC  A-­‐List  is  consistent  with  our  commitment  to   greater  corporate  transparency,”  said  Dr.  H.  Joseph  Reiser,  CEO  of  Cortendo.     “Registration  on  the  NOTC  A-­‐List  is  an  important  step  in  our  growth  strategy   and  will  allow  access  to  a  broader  investor  universe.”      

About Cortendo

Founded in 1996, Cortendo is a publicly traded, European based biopharmaceutical company that has pioneered cortisol inhibition as a treatment for Metabolic Syndrome (MES).  Lead drug candidate COR003, the 2S,4R-enantiomer of ketoconazole, is expected to enter Phase IIb clinical investigations for type 2 diabetes by the first quarter of 2012.  In parallel, Cortendo has plans to implement a broader pipeline expansion program existing of novel treatment approaches in diabetes and more near-term, revenue based opportunities.  Backed by a highly experienced leadership team, the Company’s expanded strategy will also include partnering discussions targeting the in-license of new programs in synergistic areas to provide future company growth and diversification.  For more information, please visit Cortendo’s website at www.cortendo.com.

Cortendo Forward-looking Statements

This press release contains forward-looking statements concerning Cortendo that involve a number of risks and uncertainties. All statements other than statements of historical facts included in this press release, including, without limitation, statements regarding the Company’s future financial position, strategy, anticipated investments, costs and results, plans, projects to enhance efficiency, outcomes of products development, future capital expenditures, liquidity requirements and objectives of management for future operations, may be deemed to be forward‐looking statements. These forward‐looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements or industry results to be materially different from those contemplated, projected, forecasted, estimated or budgeted, whether expressed or implied, by these forward‐looking statements. Given these risks and uncertainties, investors should not place any undue reliance on forward‐looking statements as a prediction of actual results. None of these forward‐looking statements constitutes a guarantee of the future occurrence of such facts and data or of actual results.  These statements are based on data, assumptions and estimates that the Company believes are reasonable. The forward‐looking statements contained in this document are made only as of the date hereof. The Company expressly disclaims any obligation or undertaking to release publicly any updates of any forward-looking statements contained in this press release to reflect any change in its actual results, assumptions, expectations or any change in events, factors, conditions or circumstances on which any forward‐looking statement contained in this press release is based.